• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
【24h】

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer

机译：初级预防聚乙二醇粒细胞 - 菌落刺激因子在先前治疗非小细胞肺癌患者中ramucirumab加多西紫杉醇后的临床意义

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Whether primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF) should be administered immediately after the initiation of ramucirumab plus docetaxel (DR) to prevent the occurrence of febrile neutropenia (FN) is unclear. Our retrospective study aimed to elucidate whether PEG-G-CSF could control the occurrence of FN as a result of DR in patients with previously treated non-small-cell lung cancer. Thirty-three patients with previously treated non-small-cell lung cancer who had received DR were eligible for our analysis. Of the 33 patients, 29 received prophylactic PEG-G-CSF immediately after DR, but none developed FN. However, FN was observed in 2 (50%) of the 4 patients that were not administered PEG-CSF. The overall response and disease control rates in the 29 patients with prophylactic PEG-GSF were 31% and 62%, respectively. The median progression-free and overall survival rates of the patients with and without prophylactic PEG-GSF were 177 and 163?days (P?=?0.20), and 628 and 274?days (P?=?0.13), respectively. Primary prophylactic PEG-G-CSF suppressed the occurrence of FN secondary to the administration of DR. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：在启动Ramucirumab加多西紫杉醇（DR）后，应立即给予原丙烯酸酯纤维素细胞 - 菌落刺激因子（PEG-G-CSF）以防止发热中性蛋白酶（FN）的发生尚不清楚。我们的回顾性研究旨在阐明PEG-G-CSF是否可以根据患者博士控制FN的发生，以前治疗的非小细胞肺癌博士。已收到DR的33名患有先前治疗的非小细胞肺癌的患者有资格进行分析。在33例患者中，29例接受了博士后立即接受预防性PEG-G-CSF，但没有开发FN。然而，在未施用PEG-CSF的4例患者中观察到Fn（50％）。预防PEG-GSF患​​者的总体反应和疾病控制率分别为31％和62％。患者的中位进展和整体存活率和不具有预防性PEG-GSF的患者为177和163？天（P？= 0.20），628和274？天（P？= 0.13）。初级预防性PEG-G-CSF抑制了博士施用的FN次级的发生。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号